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CASE REPORT Open Access
Iris metastasis as the initial presentation of
upper gastrointestinal tract carcinoma: a
case report
M. A. Rehman Siddiqui1,2,3* , Syed Zohaib Maroof Hussain1 and Muhammed Mubarak4
Abstract
Background: We report a case of a patient with iris metastasis as the initial manifestation of a systemic cancer:
upper gastrointestinal tract carcinoma.
Case presentation: A 24-year-old Asian man presented to our hospital with complaints of red left eye, decreased
visual acuity, pain, and photophobia for about 3 weeks with no prior history of cancer or any other medical
abnormality. Ocular examination showed a pinkish white lesion on the superonasal part of the iris. The patient’s
intraocular pressure was progressively increasing despite medications, followed by lymphadenopathy 4 weeks later.
Comprehensive examination was performed along with a complete systemic workup, which detected systemic
malignancy. Histopathology and immunohistochemistry revealed signet ring cells, which indicated an upper
gastrointestinal tract tumor as a primary source of iris metastasis. The systemic condition of the patient deteriorated
rapidly thereafter and led to his death in the 12th week of the disease.
Conclusion: A red eye with iris lesions in otherwise healthy individuals should be considered as a possible initial
manifestation of underlying systemic malignancy. Prompt referral of such patients to an oncologist is warranted.
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Introduction
Ocular metastasis is seen in 4% of systemic carcinomas.
The breast and lung are common primary sites (47% and
21%, respectively). Only 4% of ocular metastases originate
from the gastrointestinal tract [1, 2]. The choroid is the
most common site of ocular metastasis [3]. Spread of can-
cer to the iris is extremely rare. Iris metastasis may present
as stromal nodules or ill-defined iris thickening. It pre-
sents with atypical features such as pain, red eye, iridocy-
clitis, and hyphema [4, 5]. Iris metastasis as an initial
manifestation of gastrointestinal tract carcinoma is even
rarer. Only a few cases of iris metastasis from upper
gastrointestinal tract carcinoma have been reported.
To the best of our knowledge, only one case report of
iris metastasis as an initial presentation from upper
gastrointestinal tract tumor has been published [6].
In the present report, we describe a case of young man
with red eye and an iris lesion who was subsequently di-
agnosed with upper gastrointestinal tract carcinoma.
The aim of this case report is to highlight the import-
ance of systemic examination and complete workup in
patients with red eye and vitiligo.
Case presentation
A 24-year-old Asian man presented to our hospital with
complaints of redness, blurring of vision, pain, and
photophobia in the left eye for 3 weeks. The patient was
being treated for “pink eye,” but his condition did not
improve. He was generally fit and well. His family his-
tory was nonsignificant.
Ocular examination revealed a normal right eye; how-
ever, a best corrected vision of 20/30 in the left eye ac-
companied by circumcorneal injection, cells 2+ in the
anterior chamber, and vitreous cells. His intraocular
pressure (IOP) was 16mmHg at his first visit, and the
angle was open in gonioscopy. Furthermore, a pinkish
white lesion on the superonasal part of the iris was
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observed (Fig. 1). The patient was advised to have
follow-up with uveitis workup and baseline investiga-
tions; meanwhile, topical dexamethasone and cycloplegic
drops were prescribed. Of note, our patient had devel-
oped vitiligo 6 months prior to the presentation (Fig. 2).
At subsequent visits, vision of his left eye dropped per-
sistently along with constant increase in IOP from 16
mmHg to 33 mmHg in just 3 weeks. For the patient’s
raised IOP, topical and systemic hypotensive agents were
commenced. Uveitis workup was done, and most of the
test results were normal. Four weeks after presentation,
he developed right-sided supraclavicular lymphadenop-
athy, which raised the suspicion of lymphoma. He also
developed rubeosis, for which an anti-vascular endothe-
lial growth factor injection was given. Anterior chamber
paracentesis was done, which confirmed the iris lesion
as a solid mass. The anterior chamber tap was reported
as acellular. The results of radiology, including ultra-
sound of the abdomen as well as magnetic resonance
imaging of brain and orbits with contrast, were normal.
Computed tomography of the chest with contrast
showed multiple enlarged enhancing lymph nodes with
necrotic center in the cervical, mediastinal, and para-
aortic regions. Some lymph nodes were extending into
the apex of the right lung. Pretracheal lymph nodes were
enlarged as well. Testicular tumor markers β-human
chorionic gonadotropin and α-fetoprotein were normal.
Tumor markers for lymphoma, namely terminal deoxy-
nucleotidyl transferase, cyclin D1, Mum1, CD10, BCL-6,
BCL-2, CK-20, villin, and CDX2, were all negative. The
bone marrow biopsy report indicated 40–45% hypocellu-
larity. Microscopic examination revealed infiltration of
the iris by a malignant tumor composed of sheets and
nests of signet ring cells with hyperchromatic nuclei
(Figs. 3 and 4). Immunohistochemistry showed positivity
of cytokeratin 7 and MUC5, raising the possibility of
metastasis from the primary site in the upper gastro-
intestinal tract. Therefore, a final diagnosis of iris metas-
tasis secondary to upper gastrointestinal carcinoma was
made. Due to the rapidly deteriorating condition of the
patient, further investigations could not be performed.
The patient was then referred and seen by an oncolo-
gist. He received intravenous chemotherapy along with
high-dose corticosteroids. From week 8 to week 12, he
also developed massive pleural effusion resulting in
shortness of breath. He had multiple admissions to the
intensive care unit during this period; however, his con-
dition deteriorated further and led to his death in the
12th week of the disease.
Discussion
Ocular metastasis from systemic carcinomas most com-
monly occurs in the choroid; involvement of the iris is
less common [2]. One study reported that only 40 of
512 patients with uveal metastasis were found to have
involvement of the iris, the primary sites being breast
Fig. 1 Pinkish white lesion on superonasal part of iris
Fig. 2 Vitiligo on both hands
Fig. 3 Low-power photomicrograph showing a tumor nodule
embedded in surrounding fibrous adipose tissue. The tumor nodule
is surrounded by a compressed pseudocapsule. No native lymphoid
tissue is identified (Hematoxylin and eosin (H&E) stain; original
magnification, × 40)
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carcinoma in 16 cases, lung carcinoma in 11, carcinoid
tumor in 3, melanoma in 3, colonic carcinoma in 2, and
no traces of primary cancer in another 13 cases [7]. An-
other report, published in 2015, included 160 cases of
iris metastatic tumors in 107 eyes of 104 patients, and
none of the cases had the gastrointestinal tract as a pri-
mary origin of cancer [8].
In terms of diagnosis, iris tumors are sometimes mis-
diagnosed as inflammatory uveitis or iritis [6]. It is diffi-
cult to distinguish the origin of iris tumors. Diagnostic
tools used for metastatic iris tumors include clinical
findings, slit-lamp biomicroscopy, and history of sys-
temic cancer [7]. According to Shields et al., observation
of typical tumors by slit-lamp biomicroscopy is the best
method to diagnose iris metastasis in patients with prior
history of cancer [7, 8]. In case of uncertainty, fine-
needle aspiration (FNA) of the iris mass has a confirma-
tory role in reaching the diagnosis [7]. However, we were
unable to perform FNA due to our patient’s condition,
though we did perform supraclavicular lymph node bi-
opsy and immunohistochemistry.
Treatment options include chemotherapy alone, but
sometimes a combination of chemotherapy and radio-
therapy is also considered, depending on tumor advance-
ment or the patient’s response [7, 8]. Prompt treatment
with chemotherapy, which is accompanied by irradiation
if needed, helps to achieve better visual outcome, but
the systemic prognosis is usually poor [7, 8]. Median
survival from the time of diagnosis for these patients is
approximately 10–13 months [7, 8].
Only a few cases of iris metastasis from upper gastro-
intestinal tract carcinoma were reported [2, 6, 9]. How-
ever, the primary tumor was diagnosed in majority of
these cases before the presentation of iris metastasis, un-
like in our case. Only one published case report of iris me-
tastasis as a first sign of upper gastrointestinal tract
carcinoma exists. That report described a case of a 75-
year-old woman who presented with an iris tumor that
was later identified to have metastasized from gastric sig-
net ring cell adenocarcinoma [6].
Iris metastasis as the initial presentation of underlying
undiagnosed upper gastrointestinal tract carcinoma in
an otherwise healthy 24-year-old man who had devel-
oped late-onset vitiligo makes our present case report
rather distinctive.
Vitiligo is an autoimmune condition of unknown eti-
ology that causes depigmentation of different parts of
the skin. Several studies have been conducted to find the
relationship between autoimmune diseases and oncogen-
esis [10]. In one report, a 46-year-old man who was ad-
mitted to the hospital with complaints of epigastric pain
and weight loss was found, on examination, to have viti-
ligo on both the hands and forearms. Later, the patient
was diagnosed with gastric carcinoma, and surgery was
performed [11]. Although vitiligo predominates in a
large number of people, it is not yet confirmed that the
coexistence of vitiligo and tumors are merely a coinci-
dence or whether they have a common biological ex-
planation [12].
Conclusion
Iris is a rare site for secondary metastasis. Patients pre-
senting with red eyes should receive a thorough assess-
ment, particularly detailed evaluation of the iris, to rule
out rare presentations of serious conditions such as mas-
querade syndromes.
Abbreviations






All authors made contributions to manuscript design and writing. The
patient was seen and diagnosed by MARS. All authors read and finalized the
manuscript. All authors read and approved the final manuscript.
Funding
None.
Availability of data and materials
All the supporting data is included in the text.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patient’s next of kin for
publication of this case report and any accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this journal.
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